# Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

> **NCT01273610** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 40 (actual)

## Conditions studied

- Breast Neoplasms
- HER2/Neu Positive
- Geriatric Health Services

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Trastuzumab
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01273610
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-04-20
- **Primary completion:** 2018-02-22
- **Final completion:** 2026-05-19
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273610, "Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01273610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*